Enslein v. Di Mase

CourtDistrict Court, W.D. Missouri
DecidedSeptember 11, 2019
Docket4:16-cv-09020
StatusUnknown

This text of Enslein v. Di Mase (Enslein v. Di Mase) is published on Counsel Stack Legal Research, covering District Court, W.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Enslein v. Di Mase, (W.D. Mo. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI WESTERN DIVISION

JERALD S. ENSLEIN, in his capacity as ) Chapter 7 Trustee for Xurex, Inc., ) ) Plaintiff, ) ) vs. ) Case No. 16-09020-CV-W-ODS ) GIACOMO E. DI MASE, et al., ) ) Defendants. )

ORDER GRANTING IN PART, DENYING IN PART, AND DEFERRING IN PART PLAINTIFF’S MOTIONS IN LIMINE

Pending are Plaintiff Jerald Enslein’s motions in limine. Doc. #450. Defendants Dietmar Rose, Lee Kraus, Robert Olson, and Steve McKeon filed responses (Docs. #467, 478, 488) to Plaintiff’s motions, but no other defendant has filed a response, and the time for doing so has passed. See Doc. #432. As set forth below, Plaintiff’s motions in limine are granted in part, denied in part, and deferred in part. The parties are reminded these rulings are interlocutory. Thus, the denial of a request to bar evidence at this juncture preserves nothing for review, and the parties may re-assert their objections at trial if they deem it appropriate to do so. Evidence barred by this Order shall not be discussed in the jury’s presence (including during opening statements) without leave of the Court. The parties are free to suggest (out of the jury’s presence) that something has occurred during the trial justifying a change in the Court’s interlocutory ruling.

(1) Experts Not Disclosed Plaintiff moves to exclude any testimony that would constitute expert opinion from any person not disclosed as an expert by the deadline set by the Court. He contends the only experts who were timely disclosed are Michele Pavone, Robert Reilly, and Jamil Baghdachi. Doc. #250, at 2. Olson and McKeon do not object to this motion so long as the deposition testimony of former Xurex scientist John Lowry is not excluded. Doc. #488, at 2. Olson and McKeon contend Lowry did not proffer an expert opinion, and thus, this motion in limine should not limit his testimony. Id.1 Rose, who is pro se, states he could not be expected to understand the Federal Rules of Civil Procedure, and know he should have disclosed that he wanted to offer expert opinion testimony. Doc. #467, at 3. He also argues he is “more than qualified as an expert in economic analysis and damage assessment to cross examine” Reilly. Id. Rose also states he did not know he would be excluded from cross-examining Reilly, but Plaintiff’s motion does not limit Rose’s ability to cross-examine any experts at trial. Kraus argues this motion opens the door to Plaintiff characterizing any witness’s testimony as “expert opinion.” Doc. #478, at 8. Kraus also contends he “qualified as a financial expert who can offer expert opinion on valuation,” and other witnesses, such as Lowry, may qualify as an expert. Id. While Kraus is pro se at this juncture in the case, he was represented by counsel when the Court’s Scheduling and Trial Order, which is discussed infra, was entered. According to the Federal Rules of Civil Procedure, “a party must disclose to the other parties the identity of any witness it may use at trial to present evidence under Federal Rule of Evidence 702, 703, or 705.” Fed. R. Civ. P. 26(a)(2)(A). This disclosure requirement was also outlined in the Court’s Scheduling and Trial Order. Doc. #38, at 1-2. The requirement was also referenced in two other Orders. Doc. #120, at 1 (stating “the defendants shall designate any expert witnesses they intend to call at trial….”); Doc. #174, at 1 (stating “the defendants shall designate any expert witnesses [they] intend to call at trial….,” and noting “[t]his paragraph applies to all witnesses from whom expert opinions will be elicited, regardless of whether or not the witness was specially retained to provide trial testimony.”). If a party fails to identify an expert

1 Alternatively, Olson and McKeon argue that if the Court concludes any portion of Lowry’s testimony constitutes expert testimony, the Court should admit the testimony “as a newly designated expert witness, solely for any matters offered in his deposition that the Court deems to require an expert designation.” Doc. #488, at 4. They contend the belated designation is harmless because Lowry was deposed and there is no danger of unfair surprise to Plaintiff. Doc. #488, at 4-5. Neither party provides a copy of Lowry’s deposition or identify where in the record the Court may find the deposition. In addition to not having the benefit of Plaintiff’s response, the Court does not have enough information to consider Olson and McKeon’s alternative request at this time. witness, “the party is not allowed to use that…witness to supply evidence…at a trial, unless the failure was substantially justified or is harmless.” Fed. R. Civ. P. 37(c)(1). If a party intended to call Lowry, Rose, and/or Kraus to offer expert testimony, the parties was required to disclose Lowry, Rose, and/or Kraus pursuant to Rule 26(a)(2)(A) and the Court’s Scheduling and Trial Order. Because these individuals were not disclosed as expert witnesses, they are prohibited from testifying as expert witnesses at trial. Thus, Plaintiff’s motion in limine is granted. The Court’s ruling on this motion does not preclude Lowry, Rose, and Kraus from testifying as lay witnesses.

(2) Test Reports Plaintiff asks the Court to “preclude admission of the contents of test reports (including…through admitting the reports themselves) of any Xurex products for the truth of the statements therein.” Doc. #450, at 3. He argues the reports are hearsay. He also maintains the reports were prepared by individuals who hold themselves out as experts, but those individuals were not designated as experts and were not deposed. Finally, he contends admitting the reports will lead to mini-trials regarding the preparation of materials sampled, formulations used, testing environment conditions, persons involved in the chain of custody, and testing methodology. Kraus objects to this motion arguing “the very core of this matter…[is] the question of commercial viability of Xurex products.” Doc. #478, at 9. He claims the Di Mases entered into licensing agreements and purchased DuraSeal Pipe based on the belief that Xurex’s products were commercially viable. He argues evidence demonstrating the lack of viability of Xurex’s products and the time that information was known to those involved in this matter are relevant. Olson and McKeon argue Plaintiff’s motion is overbroad because it seeks to not only exclude the admission of the test reports but also prohibit Defendants from simply referring to the test reports. Olson and McKeon contend this evidence is relevant, probative, and admissible because it demonstrates what Defendants knew about the testing efforts. Also, the evidence “may be offered to show what information guided Defendants’ decision-making process, as well as for rebuttal, corroboration of Defendants’ testimony about…product performance [concerns], impeachment, and other non-hearsay purposes.” Doc. #488, at 5. Rose does not specifically object to this motion. See Doc. #467. Because at least some Defendants relied, in part, on one or more of the test reports when rendering business decisions, the test reports appear to be relevant. However, it is unclear if the test reports fall within an exception to the hearsay rule or if a foundation can be laid for the test reports. Without additional information, the Court cannot issue a ruling on this motion, and therefore, it defers consideration of this motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Enslein v. Di Mase, Counsel Stack Legal Research, https://law.counselstack.com/opinion/enslein-v-di-mase-mowd-2019.